Bank of New York Mellon Corp lessened its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 19.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 89,534 shares of the company’s stock after selling 21,735 shares during the quarter. Bank of New York Mellon Corp’s holdings in Takeda Pharmaceutical were worth $1,159,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of the stock. Raymond James & Associates boosted its position in Takeda Pharmaceutical by 5.3% in the 2nd quarter. Raymond James & Associates now owns 255,762 shares of the company’s stock worth $3,310,000 after purchasing an additional 12,862 shares in the last quarter. Blue Trust Inc. boosted its holdings in Takeda Pharmaceutical by 74.0% during the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after buying an additional 2,330 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its position in Takeda Pharmaceutical by 15.9% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 29,870 shares of the company’s stock valued at $387,000 after buying an additional 4,107 shares during the period. Tsfg LLC increased its holdings in Takeda Pharmaceutical by 8.3% in the second quarter. Tsfg LLC now owns 25,639 shares of the company’s stock valued at $332,000 after buying an additional 1,965 shares in the last quarter. Finally, OLD National Bancorp IN raised its position in shares of Takeda Pharmaceutical by 7.9% in the second quarter. OLD National Bancorp IN now owns 31,261 shares of the company’s stock worth $405,000 after acquiring an additional 2,297 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.
Takeda Pharmaceutical Price Performance
NYSE:TAK opened at $14.80 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.26 and a debt-to-equity ratio of 0.65. Takeda Pharmaceutical Company Limited has a 52 week low of $12.57 and a 52 week high of $16.06. The stock’s 50-day moving average price is $14.32 and its 200-day moving average price is $13.76. The stock has a market capitalization of $47.09 billion, a PE ratio of 26.91, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54.
Takeda Pharmaceutical Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Articles
- Five stocks we like better than Takeda Pharmaceutical
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- How to Invest in Insurance Companies: A GuideĀ
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- 5 Top Rated Dividend Stocks to Consider
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.